Form 4: GRI Bio Director Acquires 30,297 Shares Through Stock Options

David Charles Baker, a director at GRI Bio, Inc., acquired 30,297 shares through stock options at a price of $0.6857 per share.

Summary

• David Charles Baker, a director of GRI Bio, Inc., exercised stock options to acquire 30,297 shares of common stock.
• The transaction occurred on January 23, 2025.
• The exercise price for the stock options was $0.6857 per share.
• The stock options were granted on January 23, 2025, and expire on January 23, 2035.
• Following the transaction, Mr. Baker directly owns 30,297 shares.

Sentiment

Score: 7

Explanation: The transaction is a routine insider purchase, which is generally viewed positively as it indicates confidence from a director. However, it is not a major event that would significantly impact the company's valuation.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for a company that uses stock options as part of its compensation package. It is common for directors to acquire shares through options.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotech sector.
• The exercise price of $0.6857 per share is specific to GRI Bio and would need to be compared to the market price of the stock at the time of the grant and exercise to determine if it is in line with industry standards.
• The 10-year expiration period for the options is also typical.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

stock options, insider trading, share acquisition, GRI Bio, director, equity